Dimensional Fund Advisors LP Sells 15,838 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Dimensional Fund Advisors LP decreased its position in Regeneron Pharmaceuticals by 2.7%, owning 571,187 shares worth approximately $362 million after selling 15,838 shares in the first quarter.
• Analysts have mixed views on the stock, with a consensus rating of "Moderate Buy" and an average target price of $838, while some firms have recently downgraded their ratings.
• Regeneron Pharmaceuticals reported strong earnings with an earnings per share (EPS) of $12.89 for the last quarter, surpassing estimates and reflecting a 3.6% year-over-year revenue growth.

Dimensional Fund Advisors LP decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 571,187 shares of the biopharmaceutical company's stock after selling 15,838 shares during the period. Dimensional Fund Advisors LP owned about 0.52% of Regeneron Pharmaceuticals worth $362,268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $27,000. Tompkins Financial Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Finally, Curat Global LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on REGN shares. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $829.65.

Regeneron Pharmaceuticals Stock Down 0.4%

Shares of REGN stock traded down $2.13 on Tuesday, reaching $571.78. 854,560 shares of the company's stock traded hands, compared to its average volume of 1,109,174. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The business's 50 day moving average price is $545.33 and its two-hundred day moving average price is $593.59. The company has a market capitalization of $60.60 billion, a P/E ratio of 14.41, a price-to-earnings-growth ratio of 1.93 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The company had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company earned $11.56 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.